Sabse acche Pharma & Healthcare funds
Pharma, hospitals aur diagnostics — defensive growth.
Data updated · 19 direct-growth funds, 0–100 Smart Score se rank kiye hue
| ⚖ VS | Fund | Score ↓ | Faisla | 1Y | 3Y | 5Y | Sharpe | Sortino | Std Dev | Alpha | Beta | VR★ | P/E | Expense | AUM | Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities SBI | 83 | Strong Buy | 9.3% | 21.5% | 17.3% | 1.12 | 1.70 | 14.8 | 5.7 | 0.83 | — | 56.7 | 1.01% | ₹5.9k Cr | 13.8y | |
| HDFC Pharma And Healthcare HDFC | 82 | Strong Buy | 16.8% | 27.8% | — | 1.39 | 2.19 | 16.3 | 10.9 | 0.89 | — | 48.5 | 1.03% | ₹3.5k Cr | 3.1y | |
| Invesco India Pharma and Healthcare Invesco | 68 | Buy | — | — | — | — | — | — | — | — | — | 64.5 | 0.59% | ₹436 Cr | 0.1y | |
| Mirae Asset Healthcare Mirae Asset | 67 | Buy | 11.3% | 21.0% | 15.0% | 0.96 | 1.50 | 16.4 | 3.5 | 0.94 | — | 47.5 | 0.62% | ₹3.5k Cr | 8.4y | |
| DSP Healthcare DSP | 67 | Buy | 10.3% | 19.3% | 15.0% | 0.98 | 1.45 | 15.2 | 4.6 | 0.79 | — | 35.2 | 0.75% | ₹3.8k Cr | 7.9y | |
| Kotak Healthcare Kotak | 63 | Buy | 15.9% | — | — | 0.87 | 1.22 | 14.5 | 12.5 | 0.68 | — | 50.6 | 1.04% | ₹838 Cr | 2.9y | |
| UTI Healthcare UTI | 60 | Hold | 8.0% | 20.9% | 14.8% | 1.02 | 1.57 | 16.2 | 4.8 | 0.90 | — | 40.8 | 1.34% | ₹1.4k Cr | 13.8y | |
| ICICI Pru Healthcare ICICI Pru | 59 | Hold | 0.7% | 20.0% | 15.3% | 0.94 | — | 16.4 | 3.6 | 0.90 | — | — | 1.32% | ₹6.9k Cr | 8.3y | |
| PGIM India Healthcare PGIM India | 51 | Hold | 12.9% | — | — | 0.15 | 0.20 | 13.1 | 7.3 | 0.65 | — | 51.8 | 0.96% | ₹130 Cr | 1.9y | |
| WhiteOak Capital Pharma And Heathcare WhiteOak | 50 | Hold | 11.6% | — | — | — | — | — | — | — | — | 51.0 | 1.09% | ₹927 Cr | 2.7y | |
| Bajaj Finserv Healthcare Bajaj Finserv | 43 | Avoid | 10.8% | — | — | -0.05 | -0.07 | 13.5 | 3.3 | 0.68 | — | 48.1 | 0.90% | ₹405 Cr | 1.8y | |
| ABSL Pharma And Healthcare Aditya Birla Sun Life | 41 | Avoid | 8.3% | 18.6% | 13.2% | 0.92 | 1.41 | 15.6 | 2.6 | 0.90 | — | 47.1 | 1.07% | ₹1.1k Cr | 7.3y | |
| LIC MF Healthcare LIC | 33 | Avoid | 4.8% | 19.7% | 11.5% | 0.93 | 1.39 | 16.4 | 3.5 | 0.89 | — | 51.9 | 1.37% | ₹99 Cr | 7.7y | |
| Nippon India Pharma Nippon India | 32 | Avoid | 3.2% | 16.1% | 12.8% | 0.81 | 1.11 | 15.1 | 1.1 | 0.85 | — | 38.5 | 1.00% | ₹9.2k Cr | 13.8y | |
| Quant Healthcare Quant | 31 | Avoid | 10.7% | 18.8% | — | 0.83 | 1.06 | 18.4 | 3.6 | 0.88 | — | 27.0 | 1.51% | ₹431 Cr | 3.3y | |
| Baroda BNP Paribas Health And Wellness Baroda BNP Paribas | 28 | Avoid | 3.6% | — | — | -0.40 | -0.54 | 11.7 | 1.5 | 0.57 | — | 44.6 | 1.51% | ₹487 Cr | 1.4y | |
| ITI Pharma And Healthcare ITI | 27 | Avoid | 3.0% | 17.3% | — | 0.81 | 1.14 | 16.8 | 1.2 | 0.94 | — | 47.1 | 0.92% | ₹266 Cr | 5.0y | |
| Tata India Pharma & Healthcare Tata | 27 | Avoid | -0.3% | 16.8% | 13.5% | 0.79 | 1.15 | 16.8 | -0.8 | 0.99 | — | 40.3 | 1.07% | ₹1.5k Cr | 10.8y | |
| Bandhan Healthcare Bandhan | 24 | Avoid | — | — | — | — | — | — | — | — | — | 39.4 | 1.31% | ₹333 Cr | 0.9y |
Pharma & Healthcare — Jhatpat jawaab
›Abhi sabse accha Pharma & Healthcare mutual fund kaun sa hai?
SBI Healthcare Opportunities abhi 19 Pharma & Healthcare funds mein #1 hai — FundLens Smart Score 83/100 (Strong Buy). 3 saal ka return 21.5%, 5 saal ka 17.3%, expense ratio 1.01% (direct plan). Ranking 22 Oct 2026 ke data se bani hai.
›Kis Pharma & Healthcare fund ka risk-adjusted return sabse accha hai?
Sortino ratio ke hisaab se HDFC Pharma And Healthcare category mein sabse aage hai — 2.19 (Sharpe 1.39). Matlab girawat ke har unit risk par sabse zyada return.
›Sabse kam expense ratio wala Pharma & Healthcare fund kaun sa hai?
Invesco India Pharma and Healthcare — saalana 0.59% (direct plan), category mein sabse kam. Kam fees lambe samay mein aapke favour mein compound hoti hai.
›AUM ke hisaab se sabse chhota Pharma & Healthcare fund kaun sa hai?
LIC MF Healthcare — ₹99 Cr, category mein sabse chhota. Chhote funds phurteele ho sakte hain, par size ko akeli khoobi mat maano.
›Pharma & Healthcare fund mein kitne samay ke liye invested rehna chahiye?
Pharma & Healthcare funds ka risk bahut ooncha hota hai, isliye aam taur par 7+ saal ka nazariya samajhdaari hai. Pharma, hospitals aur diagnostics — defensive growth. Yeh research hai, investment advice nahi.
Yahi jawaab chat mein chahiye? FundLens se poochho